ClinicalTrials.gg
RecruitingNCT06623500Updated Oct 2, 2024

Iodine Nutrition Status and Clinical Characteristics of Thyroid Cancer

An observational study in Thyroid Cancer, sponsored by Shandong Provincial Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-10-02.

Sponsored by Shandong Provincial Hospital · Observational

How we know

From the registry’s dates

  • Started Jan 2012; still recruiting 14 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,600
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 160 studies in Thyroid Neoplasms with a site in China — 65 open to participants now, 72 under way, 6 of them phase 3. Thyroid Neoplasms · China.

Planned enrollment
9th of 52
1,600 · median 300
Started
2012
the only one that year
Observational
52 of 160
25 open now
Primary completion
2026-12
later than 28 of 71 live
Registered
111th of 160
by date
Lead sponsor
4 of 160
Shandong Provincial Hospital

Among the 160 studies in Thyroid Neoplasms with a site in China, this one is the 9th largest by planned enrollment of the 52 observational ones that give a count, is the only one that started in 2012, is one of 52 observational ones, reaches primary completion later than 28 of the 71 other live ones, and was the 111th registered.

Thyroid Neoplasms

785 studies on the registry are indexed under Thyroid Neoplasms; 203 are open to participants now.

Browse Thyroid Neoplasms studies →

Open to participants now

65 of the 160 studies in Thyroid Neoplasms with a site in China are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 151 Thyroid Neoplasms studies recruiting now, 95 (63%) set no upper age limit and 27 (18%) stop at 75 or younger; 36 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 160 studies in Thyroid Neoplasms with a site in China, or all of them as a file.
02

Study summary

The effect of iodine nutritional status on thyroid cancer has been controversial for many years. We designed a prospective cohort study that recruiting patients in different iodine areas who underwent thyroid cancer surgery in branch hospitals from 2012 to 2019,and follow up their clinical outcomes. We aimed to analyse the relationship between regional iodine nutrition level and pathological types, clinical features, and prognosis of thyroid cancer.

Read the detailed description

Three sub centers were selected in high iodine (Jining/Liaocheng/Heze) and moderate iodine (Jinan/Shenyang/Haerbin) areas respectively. Patients lived in the above-mentioned regions for at least 5 years and diagnosed as thyroid cancer and underwent thyroid surgery in branch hospitals from 2012 to 2019 were recruited.

03

Conditions studied

  • Thyroid Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Three sub centers were selected in high iodine (Jining/Liaocheng/Heze) and moderate iodine (Jinan/Shenyang/Haerbin) areas respectively. Patients lived in the above-mentioned regions at least for 5 years who was diagnosed as thyroid cancer and underwent thyroid surgery in branch hospitals from 2012 to 2019 were recruited.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age range: 18\~65 years old, gender not limited;
  2. Living in the selected region for at least 5 years;
  3. Patients who underwent thyroid surgery at various research centers were diagnosed with thyroid cancer;
  4. The clinical data (general information、surgical scope 、pathological report、utrasonic report, etc )of the case is complete.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosed as other types of cancer or thyroid cancer;
  2. There are serious comorbidities such as heart, liver, and kidney diseases present;
  3. Unable to follow up on prognostic information.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,600 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Excessive iodine group

    Residents with thyroid cancer who have lived in high iodine areas for a long time (5 years or more). According to the report of Shandong Institute of Endemic Disease Prevention and Control, three sub centers were selected in Excessive iodine group (Jining/Liaocheng/Heze).

    Dietary Supplement: Iodine excess

  • Suitable iodine group

    Residents with thyroid cancer who have lived in suitable iodine areas for a long time (5 years or more). According to the report of Shandong Institute of Endemic Disease Prevention and Control, three sub centers were selected in suitable iodine (Jinan/Shenyang/Haerbin) areas.

    Dietary Supplement: Iodine suitable

Interventions

  • Dietary supplementIodine excess

    Iodine excess areas: water iodine ≥100μg/L; or urinary iodine concentration (median urinary iodine levels in children aged 8-10 years old)≥300μg/L

  • Dietary supplementIodine suitable

    Iodine suitable areas:water iodine ≥40μg/L and ≤100μg/L; or urinary iodine concentration(median urinary iodine levels in children aged 8-10 years old) 100-199μg/L.

06

What researchers measure

Primary outcomes

  1. Number of participants with recurrence

    Recurrence: diagnosed as the same type of thyroid cancer again by pathology

    Time frame: from enrollment to the final follow-up at 5 years

  2. Number of participants with distant metastasis

    Distant metastasis: Pathological confirmed thyroid cancer occurring outside the thyroid gland

    Time frame: from enrollment to the final follow-up at 5 years

  3. All-cause mortality

    The ratio of the total number of deaths caused by various reasons during the research period to the number of participants

    Time frame: from enrollment to the final follow-up at 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2012 (actual). Primary completion is estimated for Dec 2026, 179 months after the start.

Of 103 non-industry observational studies under Thyroid Neoplasms, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 311. This study's planned 179 months is above that.

Counting every sponsor, half of 112 studies reached it within 63 months; a quarter within 26 and three quarters within 311.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2024
First posted
Oct 2, 2024
StartActual
Jan 1, 2012
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 31, 2026
Last update
Oct 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06623500
Lead sponsor
Shandong Provincial Hospital
Responsible party
Hai-qing Zhang (Chief physician, Shandong Provincial Hospital) — Principal investigator
First posted
Oct 2, 2024
Start date
Jan 1, 2012
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 2, 2024

Study contacts

Qingling Guo
Contact
guoqinglingqhb@163.com
+86 0531-68776375

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion